Artelo Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.55
- Today's High:
- $1.63
- Open Price:
- $1.55
- 52W Low:
- $1.39
- 52W High:
- $7.2
- Prev. Close:
- $1.69
- Volume:
- 64888
Company Statistics
- Market Cap.:
- $5.37 million
- Book Value:
- 6.176
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.42%
- Return on Equity TTM:
- -47.38%
Company Profile
Artelo Biosciences Inc had its IPO on 2017-11-14 under the ticker symbol ARTL.
The company operates in the Healthcare sector and Biotechnology industry. Artelo Biosciences Inc has a staff strength of 7 employees.
Stock update
Shares of Artelo Biosciences Inc opened at $1.55 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.55 - $1.63, and closed at $1.58.
This is a -6.51% slip from the previous day's closing price.
A total volume of 64,888 shares were traded at the close of the day’s session.
In the last one week, shares of Artelo Biosciences Inc have slipped by -15.51%.
Artelo Biosciences Inc's Key Ratios
Artelo Biosciences Inc has a market cap of $5.37 million, indicating a price to book ratio of 0.395 and a price to sales ratio of 0.
In the last 12-months Artelo Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-7440756. The EBITDA ratio measures Artelo Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Artelo Biosciences Inc’s operating margin was 0% while its return on assets stood at -29.42% with a return of equity of -47.38%.
In Q0.66666666666667, Artelo Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Artelo Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Artelo Biosciences Inc’s profitability.
Artelo Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.1422. Its price to sales ratio in the trailing 12-months stood at 0.
Artelo Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $20.42 million
- Total Liabilities
- $998000.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Artelo Biosciences Inc ended 2024 with $20.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $20.42 million while shareholder equity stood at $19.40 million.
Artelo Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $998000.00 in other current liabilities, 3000.00 in common stock, $-31021000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.89 million and cash and short-term investments were $17.53 million. The company’s total short-term debt was $40,000 while long-term debt stood at $0.
Artelo Biosciences Inc’s total current assets stands at $18.32 million while long-term investments were $0 and short-term investments were $10.65 million. Its net receivables were $0 compared to accounts payable of $905000.00 and inventory worth $0.
In 2024, Artelo Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Artelo Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.58
- 52-Week High
- $7.2
- 52-Week Low
- $1.39
- Analyst Target Price
- $18.33
Artelo Biosciences Inc stock is currently trading at $1.58 per share. It touched a 52-week high of $7.2 and a 52-week low of $7.2. Analysts tracking the stock have a 12-month average target price of $18.33.
Its 50-day moving average was $1.94 and 200-day moving average was $2.35 The short ratio stood at 0.94 indicating a short percent outstanding of 0%.
Around 93.6% of the company’s stock are held by insiders while 415.4% are held by institutions.
Frequently Asked Questions About Artelo Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.